Caption Management’s Vir Biotechnology VIR Stock Holding History

Caption Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,600	Closed	-$64.4K	–	2062
2025 Q2	$63.5K	Hold	12,600	–	–	﹤0.01%	1338
2025 Q1	$81.6K	Buy	+12,600	New	+$112K	﹤0.01%	1371
2024 Q2	–	Sell	-10,925	Closed	-$111K	–	1535
2024 Q1	$111K	Buy	+10,925	New	+$111K	﹤0.01%	1046
2023 Q2	–	Sell	-7,500	Closed	-$188K	–	1427
2023 Q1	$175K	Buy	+7,500	New	+$192K	﹤0.01%	933

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Caption Management's VIR Position: Q3 2025 in Review

Caption Management sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 12,600 shares — an estimated $64.4K sold.

Caption Management first reported a position in VIR in Q1 2023 and held it in 4 quarters. The position peaked at $175K in Q1 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

Caption Management reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
Caption Management sold 12,600 Vir Biotechnology shares in Q3 2025, an estimated $64.4K.
Caption Management first reported a position in Vir Biotechnology in Q1 2023 and held it in 4 quarters.
Caption Management's Vir Biotechnology position peaked at $175K in Q1 2023.
213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.